- In recent weeks, Ameriprise Financial has faced insider share sales by several top executives, the planned retirement of a key Advice & Wealth Management leader, and an SEC fine related to compliance failures involving unapproved electronic messaging platforms.
- At the same time, its Columbia Threadneedle asset management arm was ranked by Barron's among the top fund families across 1-, 5-, and 10-year periods, underscoring the group’s long-term investment performance.
- We’ll examine how the insider selling and leadership transition might influence Ameriprise’s previously discussed technology, recruitment, and capital return investment narrative.
Outshine the giants: these 21 early-stage AI stocks could fund your retirement.
Ameriprise Financial Investment Narrative Recap
To own Ameriprise Financial, you need to be comfortable with a fee-based wealth and asset management model that leans on advisor productivity, asset growth, and disciplined capital returns. Recent insider selling, an executive retirement in Advice & Wealth Management, and an SEC messaging-related fine may affect sentiment, but do not materially alter the near term catalyst around technology-driven productivity or the key risk of market-driven revenue volatility and competitive pressure on adviser recruiting.
The Columbia Threadneedle recognition in Barron’s Best Fund Families of 2025 looks particularly relevant here, given concerns around asset management outflows and institutional redemptions. Ranking in the top ten for 1 and 5 years and fifth over 10 years highlights fund performance at a time when Ameriprise is investing heavily in technology and advice capabilities that depend on credible investment products to support adviser productivity and reinforce the case for continued capital returns.
Yet beneath the awards and capital return story, investors should be aware that regulatory and compliance missteps could still...
Read the full narrative on Ameriprise Financial (it's free!)
Ameriprise Financial's narrative projects $20.7 billion revenue and $4.0 billion earnings by 2028. This requires 4.4% yearly revenue growth and a roughly $0.8 billion earnings increase from $3.2 billion.
Uncover how Ameriprise Financial's forecasts yield a $538.60 fair value, a 16% upside to its current price.
Exploring Other Perspectives
Compared with the baseline view, the most optimistic analysts assume Ameriprise can lift earnings to about US$4.2 billion by 2028, yet the latest insider selling and SEC fine show why your own view on regulatory and interest rate risks may lead you to see those forecasts very differently.
Explore 3 other fair value estimates on Ameriprise Financial - why the stock might be worth as much as 64% more than the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Ameriprise Financial research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Ameriprise Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ameriprise Financial's overall financial health at a glance.
Contemplating Other Strategies?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
- AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com